By John George – Senior Reporter, Philadelphia Business Journal
Johnson & Johnson unveiled plans Wednesday to build a more than $1 billion cell therapy manufacturing plant in Montgomery County.
The plant will be built on a 154-acre property at 1201 Sumneytown Pike in Spring House, Lower Gwynedd Township. The site is about a mile from Johnson & Johnson's 171-acre research and development campus in Spring House. That campus, at McKean and Welsh roads, houses about 2,500 employees.
The Sumneytown Pike site for the new manufacturing plant has an existing 157,000-square-foot building but is otherwise undeveloped. It was sold by Gwynedd Mercy University for $31.5 million in 2022 to Beacon Capital Partners, a Boston real estate investment firm that owns the nearby Spring House Innovation Park. Johnson & Johnson (NYSE: JNJ) said it would own and develop the property, and the existing building at the site will be torn down.
The project is part of Johnson & Johnson's previously announced plan to invest $55 billion by early 2029 to manufacture the "vast majority" of its advanced medicines, including cell therapies that use living and modified cells to treat disease, in the United States.
“By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families," Joaquin Duato, CEO of Johnson & Johnson, said in a statement.
The state is providing a $41.5 million economic package to support the Johnson & Johnson project. That package includes up to $12 million in tax credits through Pennsylvania's Qualified Manufacturing Innovation and Reinvestment Deduction program, up to $2 million in tax credits through the state's Manufacturing Tax Credit program, a $15 million grant through the Pennsylvania Strategic Investments to Enhance Sites program and a $10 million Pennsylvania First grant.
The state has also committed to providing a Redevelopment Assistance Capital Program award of up to $2.5 million to a local community college or technical school to help create a workforce development training program that would serve as a talent pipeline for the company in Montgomery County.
In a statement, Rick Siger, secretary of the Pennsylvania Department of Community and Economic Development, called Johnson & Johnson's decision to reinvest in Montgomery County "another huge win" for the state that further expands its life sciences ecosystem.
Gov. Josh Shapiro said in a statement that the project is further proof Pennsylvania is emerging as a "powerhouse" for innovation and manufacturing in the life sciences.
Johnson & Johnson is not disclosing the square footage of the Spring House plant, which it said will expand its manufacturing capacity as it advances its portfolio and pipeline of cell therapy medicines for cancer, immune-mediated and neurological diseases. The company has one cell therapy, Carvykti, approved by the Food and Drug Administration. The medicine is used to treat relapsed or refractory multiple myeloma.
Johnson & Johnson previously operated its Spring House campus as a Janssen Research & Development site. The company started phasing out the Janssen Pharmaceuticals name in 2023 as part of a corporate rebranding. Johnson & Johnson still maintains Janssen Biotech in neighboring Horsham, and the division will operate the new Spring House plant.
Full story: https://www.bizjournals.com/philadelphia/news/2026/02/18/johnson-johnson-cell-therapy-spring-house.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.